Acute neurological manifestations associated with the SARS-CoV-2 virus
- Funded by Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)
- Total publications:2 publications
Grant number: 2020/05984-2
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$31,790.8Funder
Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)Principal Investigator
PendingResearch Location
BrazilLead Research Institution
Universidade de São PauloResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Subject
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
In 2019, an outbreak of respiratory disease associated with a new coronavirus, SARS-CoV-2, began in the city of Wuhan, China. Since then, this highly transmissible virus has motivated extreme isolation measures around the world, in an attempt to mitigate the infection of entire populations, concomitantly saturating medical services and collapsing health systems. Several coronaviruses are associated with neurological syndromes such as encephalitis, myelitis and Guillain-Barré syndrome, among them SARS-CoV-1, phylogenetically the human coronavirus closest to SARS-CoV-2. Thus, it is expected that similar manifestations affect patients in the current epidemic. OBJECTIVES: To characterize the epidemiological, clinical, laboratory, electrophysiological and radiological profile of patients affected by myelitis, encephalitis and / or acute peripheral polyneuropathy in the presence of an epidemic associated with the SARS-Cov-2 virus. METHODS: This is a prospective observational study, which will evaluate the epidemiological, clinical, laboratory, electrophysiological and radiological characteristics of patients diagnosed with encephalitis, myelitis and / or acute peripheral polyneuropathy during the SARS-Cov-2 epidemic period, assisted in co-participant institutions. Patients who are considered suspected cases of SARS-CoV-2 will be selected according to criteria defined by the Ministry of Health (MS) and the World Health Organization (WHO) in the presence of proven community transmission, who present concomitant or subsequent clinical suspicion (up to 60 days after an event associated with SARS-CoV-2) of viral encephalitis, viral myelitis and / or acute peripheral polyneuropathy.
Publicationslinked via Europe PMC
Last Updated:3 days ago
View all publications at Europe PMC